The “Antibody Contract Manufacturing Market, 2020-2030
KeyInclusions
§ A detailed review ofthe overall landscape of companies, offering contract services for themanufacturing of antibodies, along with information on year of establishment,company size, scale of operation (preclinical, clinical and commercial),location of headquarters, number of manufacturing facilities and location ofthese facilities, type of antibody manufactured (monoclonal antibodies,bispecific antibodies and polyclonal antibodies), type of expression systemsused (mammalian, microbial and others), fill / finish operations andaffiliations to regulatory agencies.
§ A competitivenessanalysis of key players engaged in this domain, featuring an assessment basedon their supplier strength (related to the experience of a contractmanufacturer), and service strength (which takes into account the sizeof service portfolio and scale of operation).
§ A benchmark analysis,highlighting the key focus areas of small, mid-sized and large companies,comparing their existing capabilities within and beyond their respective(geography-based) peer groups.
§ An analysis of thevarious partnerships pertaining to contract manufacturing of antibodies, whichhave been established since 2013, based on several parameters, such as the yearof agreement, type of partnership, project scale and focus therapeutic area.
§ An analysis of thevarious expansion initiatives undertaken by service providers, in order toaugment their respective antibody manufacturing capabilities, over the period2017-2019 (till October), taking into consideration parameters, such asyear of expansion, type of expansion (capacity expansion, facility expansionand new facility), type of antibodies manufactured and location ofmanufacturing facility.
§ An estimate of theoverall, installed capacity for manufacturing antibodies based on data reportedby industry stakeholders in the public domain; it highlights the distributionof available antibody production capacity on the basis of company size (small,mid-sized, large and very large firms), scale of operation (preclinical,clinical and commercial), and key geographical regions (North America, Europe,Asia).
§ Informed estimates ofthe annual commercial and clinical demand for antibodies, based on variousrelevant parameters, such as target patient population, dosing frequency anddose strength.
§ Elaborate profiles ofthe key industry players that offer contract manufacturing services at allscales of operation and have more than two manufacturing facilities. Eachprofile features a brief overview of the company, information on its serviceportfolio, details related to its manufacturing capabilities and facilities,and an informed future outlook.
§ A case studycomparing the key characteristics of large molecule and small molecule drugs,along with details on the various steps and challenges involved in theirrespective manufacturing processes.
§ A discussion onaffiliated trends, key drivers and challenges, under a SWOT framework, whichare likely to impact the industry’s evolution, including a Harvey ballanalysis, highlighting the relative effect of each SWOT parameter on theoverall pharmaceutical industry.
The report also features the likely distribution ofthe current and forecasted opportunity across important market segments,mentioned below:
§ Type of Antibodies
§ Monoclonal Antibodies
§ Bispecific Antibodies
§ ADCs
§ Others
§ Company Size
§ Small
§ Mid-sized
§ Large / Very Large
§ Scale of Operation
§ Preclinical / Clinical
§ Commercial
§ Type of expressionsystem used
§ Mammalian
§ Microbial
§ Key geographicalregions
§ North America
§ Europe
§ Asia and RoW
Thereport includes detailed transcripts of discussions held with the followingexperts:
§ Dietmar Katinger (ChiefExecutive Officer, Polymun Scientific)
§ David C Cunningham (Director,Corporate Development, Goodwin Biotechnology)
§ Claire Otjes (MarketingManager, Batavia Biosciences)
To request sample pages, please visit this link
Key Questions Answered
§ Whoare the leading CMOs engaged in the production of antibody-based therapeutics?
§ Whatkind of partnership models are commonly adopted by stakeholders in thisindustry?
§ Whatis the annual clinical and commercial demand for antibody-based products?
§ Whatis the current installed capacity for manufacturing of antibodies?
§ Whatare the various expansion initiatives undertaken by antibody CMOs?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
Youmay also be interested in the following titles:
1. Bispecific AntibodyTherapeutics Market (4th Edition), 2019-2030
2. Antibody DrugConjugates (ADCs) - Linker and Conjugation Technologies Market, 2019-2030
3. Antibody DrugConjugates Market (5th Edition), 2019-2030
ContactUs
GauravChaudhary
+1(415) 800 3415
gaurav.chaudhary@rootsanalysis.com
